No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK reported two sets of encouraging cancerdrug results on Monday, with fresh data for its experimental ovariancancer therapy MoRez and new interim findings for Jemperli in rectal cancer, both due to be presented at the ESMO Congress.
In ovarian cancer, updated phase I results for MoRez showed durable and meaningful responses after more than 13 months of followup, with the treatment delivering a 62% confirmed response rate at the selected phase III dose, as patients see a median 12.2month duration of response and 11.1month progressionfree survival.
GSK said safety remained broadly consistent with earlier readouts, with most serious side effects linked to bloodrelated issues and only isolated cases of lung inflammation.
Separately, GSK said its phase II AZUR1 trial showed Jemperli achieved a 76% completeresponse rate in patients with MSIH/dMMR locally advanced rectal cancer, with many avoiding chemotherapy, radiotherapy or surgery. After more than two years of followup, no recurrences have been reported among responders.
The FTSE 100-listed company said the findings support a potential organpreserving approach for eligible patients, with regulatory reviews already under way through Project Orbis.
As of 1130 GMT, GSK shares were up 0.98% at 1,912.50p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS on Sharecast
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.